Strides Pharma Science Limited
STAR · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,642.67.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%20.0%
- ✕Low debt (D/E < 0.5)0.56x
- ✓Positive free cash flow
- ✓Revenue growth > 10%11%
- ✓Earnings growing54%
- ✓Net margin ≥ 10%11.4%
- ✕Current ratio > 1.51.25
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✕Altman Z in safe zoneZ 2.53
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (20.0%).
Opportunities
- •Earnings growing (54% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~86% below our estimated fair value.
About Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.